Mannitol

Mannitol is a sugar alcohol (polyol) used as an osmotic diuretic.

  • Pharmacologic class: Osmotic diuretic
  • Does NOT cross intact BBB
  • Freely filtered at glomerulus not reabsorbed

Mechanism of Action 

1. Intravascular Osmotic Effect

  • Increases plasma osmolality
  • Pulls water from:
    • Brain parenchyma cerebral edema
    • Intraocular fluid IOP

2. Renal Effect

  • Filtered in glomerulus remains in tubule
  • Creates osmotic gradient prevents water reabsorption
  • Osmotic diuresis

 Effect on Brain 

Phase-wise effects:

  1. Immediate (minutes)
    • Plasma expansion blood viscosity
    • Reflex cerebral vasoconstriction
    • cerebral blood volume ICP
  1. Delayed (15–30 min)
    • Osmotic gradient water shifts from brain plasma
    • brain bulk ICP
  1. Rebound phenomenon 
    • Occurs if BBB disrupted
    • Mannitol enters brain reverses gradient
    • Worsening cerebral edema

 Pharmacokinetics

Parameter

Detail

Onset

5–10 min

Peak

20–60 min

Duration

4–6 hr

Half-life

~1.5–2 hr ( in renal failure)

Excretion

Renal (unchanged)

 Indications 

 Neurocritical Care

  • Raised ICP:
    • Traumatic brain injury
    • Intracranial Hemorrhage
    • Brain tumors
  • Impending herniation (emergency bolus)

 Ophthalmology

  • Acute angle-closure glaucoma IOP

  Renal / ICU

  • Prevention of AKI (controversial, NOT routine now)
  • Rhabdomyolysis (selected cases)

 Dose 

Raised ICP

  • 0.25–1 g/kg IV bolus
  • Repeat based on ICP / osmolality

Target Monitoring:

  • Serum osmolality: <320 mOsm/kg
  • Osmolar gap: <55 mOsm/kg

 Re-dosing 

Instead of fixed timing:

 Repeat 0.25–0.5 g/kg ONLY if:

  • ICP still elevated (>20–22 mmHg)
  • Clinical signs persist:
    • Pupillary changes
    • Low GCS
    • CT worsening


 Minimum interval

  • Usually 4–6 hours
  • BUT depends on:
    • Serum osmolality
    • Urine output
    • Hemodynamics

 Tapering strategy 

  1. Increase dosing interval
    • From 4 hourly 6 hourly 8 hourly
  1. Reduce dose
    • From 1 g/kg 0.5 g/kg 0.25 g/kg
  1. Stop when:
    • ICP stable
    • Osmolality approaching 300–310
    • Risk of AKI or hypovolemia

 4. When to STOP immediately

  • Serum osmolality >320 mOsm/kg
  • Osmolar gap >55
  • AKI / rising creatinine
  • Hypotension / hypovolemia
  • Pulmonary edema

Hemodynamic Effects

  • Initial:
    • Plasma expansion preload
    • May cause transient hypertension
  • Later:
    • Diuresis intravascular volume
    • Risk hypotension

 Adverse Effects

1. Volume-related

  • Early: Fluid overload pulmonary edema
  • Late: Hypovolemia hypotension

2. Electrolyte disturbances

  • Hyponatremia (dilutional, early)
  • Hypernatremia (late due to water loss)
  • Hypokalemia / Hyperkalemia

3. Renal

  • Osmotic nephrosis
  • AKI (especially if repeated high doses)

4. CNS

  • Rebound ICP (BBB disruption)

 Contraindications

  • Anuria / severe renal failure
  • Pulmonary edema / CHF
  • Active intracranial bleeding (relative; except perioperative neurosurgery)
  • Severe dehydration

 Monitoring 

  • Serum osmolality (keep <320)
  • Urine output
  • Electrolytes
  • Renal function
  • ICP (if available)

 Mannitol vs Hypertonic Saline 

Feature

Mannitol

Hypertonic Saline

Mechanism

Osmotic diuresis

Osmotic + volume expansion

Volume status

Causes diuresis

Expands intravascular volume

BP

May later

Improves BP

ICP effect

Good

Often superior

Rebound ICP

Possible

Less common

Use in shock

 Avoid

 Preferred

 Guidelines (Neurocritical Care Society / TBI guidelines):

  • Both acceptable
  • Hypertonic saline increasingly preferred, especially in hypotension

 Clinical Pearls 

  • Mannitol works only if BBB intact
  • Avoid repeated doses risk of accumulation + rebound ICP
  • If serum osmolality >320 STOP
  • Prefer hypertonic saline in:
    • Hypotension
    • Renal dysfunction

 Special ICU Considerations

  • Warm solution before use (crystallization common)
  • Use inline filter
  • Avoid in:
    • ARDS
    • Heart failure